TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042
Apr 27, 2017 12:15 pm UTC| Business
TSR-042 is the first TESARO immuno-oncology candidate to enter a registration programOngoing clinical trial expanded to enroll patients with endometrial cancerPatient-centric administration schedulewith every 6 week dosing...
Trinity Biotech Announces Results for Q1, 2017
Apr 27, 2017 12:09 pm UTC| Business
DUBLIN, Ireland, April 27, 2017 -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the...
CareTrust REIT Schedules First Quarter 2017 Earnings Call for Wednesday, May 3, 2017
Apr 27, 2017 12:05 pm UTC| Business
SAN CLEMENTE, Calif., April 27, 2017 -- CareTrust REIT, Inc. (NASDAQ:CTRE) announced today that it plans to release its first quarter 2017 financial results after the market closes on Tuesday, May 2, 2017....
New Family of maXTouch® Touchscreen Controllers Designed for Large-Screen Automotive HMI Designs
Apr 27, 2017 12:04 pm UTC| Business
CHANDLER, Ariz., April 27, 2017 -- A new family of maXTouch® touchscreen controllers is now available from Microchip Technology Inc. (NASDAQ:MCHP), a leading provider of microcontroller, mixed-signal, analog and...
Sphere 3D’s HVE VDI Technology Selected by Gollob Morgan Peddy, Certified Public Accountants
Apr 27, 2017 12:04 pm UTC| Business
SAN JOSE, Calif., April 27, 2017 -- Sphere 3D Corp. (NASDAQ:ANY), a containerization, virtualization, and data management solutions provider, today announced that Gollob Morgan Peddy PC has selected the company’s HVE...
Sphere 3D’s HVE VDI Technology Selected by Gollob Morgan Peddy, Certified Public Accountants
Apr 27, 2017 12:03 pm UTC| Business
SAN JOSE, Calif., April 27, 2017 -- Sphere 3D Corp. (NASDAQ:ANY), a containerization, virtualization, and data management solutions provider, today announced that Gollob Morgan Peddy PC has selected the company’s HVE...
Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome
Apr 27, 2017 12:03 pm UTC| Business
EMERYVILLE, Calif., April 27, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the last...